# A Trial of the Efficacy and the Safety of RO6889450 (Ralmitaront) vs Placebo in Patients With an Acute Exacerbation of Schizophrenia or Schizoaffective Disorder

> **NCT04512066** · PHASE2 · COMPLETED · sponsor: **Hoffmann-La Roche** · enrollment: 287 (actual)

## Conditions studied

- Schizophrenia, Schizoaffective Disorder

## Interventions

- **DRUG:** RO6889450
- **DRUG:** Placebo
- **DRUG:** Risperidone

## Key facts

- **NCT ID:** NCT04512066
- **Lead sponsor:** Hoffmann-La Roche
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-09-08
- **Primary completion:** 2022-06-21
- **Final completion:** 2022-06-21
- **Target enrollment:** 287 (ACTUAL)
- **Last updated:** 2023-10-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04512066

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04512066, "A Trial of the Efficacy and the Safety of RO6889450 (Ralmitaront) vs Placebo in Patients With an Acute Exacerbation of Schizophrenia or Schizoaffective Disorder". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT04512066. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*